(Reuters) – A panel of U.S. Food and Drug Administration advisers on Friday voted for the expanded use of British drugmaker AztraZeneca Plc’s experimental treatment, jointly developed with Merck & Co, for a type of prostate cancer.
The FDA panel voted 11-1 with one abstention, in favor of using the drug, Lynparza, in combination with other medications – abiraterone and prednisone or prednisolone – to treat a type of treatment-resistant prostate cancer in adult patients.
(Reporting by Mariam Sunny, Khushi Mandowara and Aditya Samal in Bengaluru; Editing by Shailesh Kuber)
